14 results about "Ribosomal protein" patented technology

The invention provides application of a paeoniflorin photoaffinity probe in screening key target protein of paeoniflorin, and relates to the technical field of chemical proteomics. The paeoniflorin photoaffinity probe has a structure as shown in a formula I, and the paeoniflorin key target proteins are 40S ribosomal protein S3 and statin 2. The paeoniflorin photoaffinity probe is applied to screening of the paeoniflorin key target proteins, so that two target proteins combined with paeoniflorin in liver cells are successfully identified; the two target proteins are respectively 40S ribosomal protein S3 (RPS3) and statin 2 (PHB2), and the two target proteins participate in the protection effect of paeoniflorin on the liver, and have the key effects of oxidation resistance, inflammation resistance, immunoregulation and the like in liver diseases.

The present disclosure provides methods for inducing cellular quiescence—defined as a reversible arrest of cell proliferation—by inhibiting ribosome biogenesis. The methods involve administering a quiescence-inducing agent, such as a small molecule inhibitor, peptide, antisense oligonucleotide, or targeted degrader, that interferes with rRNA transcription, processing, ribosomal protein synthesis, or ribosome assembly. The agent may be applied to cultured cells, tissues, organs, or organoids, across a range of cell types and species. In some embodiments, the methods reduce metabolic activity and enhance stress resistance in non-dividing or post-mitotic cells. By slowing proliferation and / or metabolism while preserving viability, these methods enable improved preservation of cells, tissues, and organs-enhancing transplantation logistics, biobanking, regenerative medicine workflows, and biological transport. Additional applications include studies of cell cycle regulation, tissue regeneration, stress biology, aging, and induction of organismal hypometabolism (e.g., torpor or hibernation). The disclosure includes examples demonstrating quiescence induction using chemical biology systems, pharmacological agents, and genetic approaches.

This invention provides an expression cassette, an expression vector, a genetically engineered strain, and their application in the preparation of malonic acid. The expression cassette includes expression cassette 1, expression cassette 2, and expression cassette 3. Expression cassette 1 includes the gene for the mitochondrial 37S ribosomal protein mS47; expression cassette 2 includes the ACC1 gene, which incorporates a mitochondrial localization signal encoding gene at its 5' end; and expression cassette 3 includes the upstream homologous arm of an endogenous ACC1 gene, which incorporates a weak promoter at its 5' end. This invention, through the expression cassette, can promote an increase in the levels of mS47 and ACC1 in mitochondria, thereby promoting the synthesis pathway of acetyl-CoA-malonyl-CoA-malonic acid (ACEA), while simultaneously reducing the level of endogenous ACC1 in the cytoplasm, avoiding competitive effects on the mitochondrial ACEA synthesis pathway, and ultimately effectively increasing malonic acid production.

The application discloses a natural fissistilarin component derivative DhpB and application thereof, and particularly application thereof as a covalent binding ubiquitinase MKRN2 target in anti-KRAS mutant lung cancer. The derivative is from a plant of Peperomia in Piperaceae, can significantly inhibit in-vivo and in-vitro proliferation of KRAS mutant non-small cell lung cancer cells, and induce tumor cell apoptosis through semi-synthetic structure optimization. DhpB is covalently combined with ubiquitinase MKRN2 abnormally expressed in KRAS mutant lung cancer cells, promotes combination of MKRN2 and small ribosomal protein RPS7, thereby promoting ubiquitination and degradation of RPS7, and causes ribosome stress-induced apoptosis of tumor cells. The application provides a new target and inhibitor for preparing a drug for treating refractory KRAS mutant lung cancer, and has a good medicinal prospect.

The invention belongs to the technical field of gene engineering, and particularly relates to a ribosomal protein N'mutant and application thereof. The ribosomal protein N'mutant is subjected to Y190D mutation, and after the ribosomal protein N 'expressed by a production strain is subjected to Y190D mutation, the yield of LNT II is increased by 28.6%, the yield of LNnT is increased by 50%, the yield of LNT is increased by 92.3%, the yield of 3'-SL is increased by 13.8%, and the yield of 6 '-SL is increased by 20%. Therefore, after the 190th amino acid of the PriA is changed from tyrosine to aspartic acid, the production capacity of the PriA is improved, and when the PriA is applied to escherichia coli for producing the human milk oligosaccharide, the yield of the human milk oligosaccharide is remarkably improved finally.

Provided are methods for using chimeric proteins to produce RNA modifications that can be detected by sequencing methods, including methods detecting relative translation rates of various mRNAs. Also provided herein are compositions comprising chimeric proteins, wherein the chimeric proteins comprise a RNA editing protein and a ribosomal protein.

The invention belongs to the technical field of plant genetic engineering and biology, and discloses a peanut endogenous strong promoter PAhRPS5 and a preparation method and application thereof, the promoter comprises PAhRPS5A, PAhRPS5B and PAhRPS5C, and the promoter respectively corresponds to the promoter of peanut genes AhRPS5A, AhRPS5B and AhRPS5C. According to the promoter, an amino acid sequence of an arabidopsis thaliana RPS5 gene is taken as a reference, peanut RPS5 candidate genes are identified through homologous retrieval, and after high-expression genes are screened through expression quantity analysis, the promoter is obtained by cloning from a peanut Yuhua flower 9326 genome by adopting a PCR (Polymerase Chain Reaction) technology; a recombinant vector containing the promoter is constructed, peanut embryogenic calluses are transformed, and functional verification shows that the promoter can drive downstream genes to be expressed in the peanut calluses. The technical bottleneck that existing peanut gene editing depends on an exogenous promoter and is poor in adaptability is solved, the application blank of the peanut endogenous strong promoter is filled, and the peanut endogenous strong promoter can be used for constructing a peanut precise gene editing system and promoting peanut breeding improvements such as stress resistance and high quality, and has important practical value and industrialization prospect.

The invention provides a method for predicting myocarditis by using circular RNAcirc0071542 and ribosomal protein RPL13A. The method comprises the following steps: a) obtaining a biological sample of a subject; b) detecting the expression level of circACSL1 in the biological sample; c) comparing the expression level of the circACSL1 with a reference value from a healthy control; and d) when the expression level of the circACSL1 is higher than the reference value, judging that the subject has a myocarditis risk or is in a myocarditis state according to a difference value between the expression level of the circACSL1 and the reference value. The circACSL1 expression level is compared with the typical expression range of a dilated cardiomyopathy (DCM) subject to generate differential diagnosis data, and the expression difference of the marker between myocarditis and DCM can be utilized to effectively assist in clinically distinguishing the two diseases with different treatment strategies and prognosis but similar clinical manifestations.

A recombinant multi-epitope immunogenic polypeptide derived from *C. bancroftian* and its applications are disclosed. The amino acid sequence of the recombinant multi-epitope immunogenic polypeptide includes a fragment of the *Mycobacterium tuberculosis* 50S ribosomal protein L7 / L12, a cytotoxic T lymphocyte epitope, a helper T lymphocyte epitope, and a linear B cell epitope, formed by tandem linkers. The nucleotide coding sequence of the polypeptide is also disclosed. This invention further discloses a recombinant expression vector containing the nucleic acid molecule, a host cell containing the recombinant expression vector, an immunogenic composition containing the recombinant multi-epitope immunogenic polypeptide, and a method for preparing the recombinant multi-epitope immunogenic polypeptide. Immuninformatics analysis results show that the polypeptide is antigenic, non-sensitizing, and non-toxic; structural prediction, molecular docking, and computer immunosimulation results suggest its application potential as a candidate immunogenic polypeptide related to *C. bancroftian*.

The application belongs to the field of anticancer active natural ingredients, and particularly relates to an anticancer active glycoprotein, a preparation method and application thereof, and an anticancer drug for female cancer, wherein the anticancer active glycoprotein is a protein chemically bonded with selenium and polysaccharide, the protein includes a peroxidase domain protein, an RNA-dependent RNA polymerase, a nucleolar 278 pre-rRNA processing Urb / Npa2 C-terminal domain-containing protein, and a ribosomal protein S12; the polysaccharide chain is a sugar unit fragment with a structure of formula 1; the hydroxyl in the polysaccharide is connected to at least one amino acid in aspartic acid, valine, glutamic acid, arginine, lysine and serine in the protein through a hydrogen bond; and the selenium bond includes at least one of Se=O and Se-C-O. The application provides a novel structure of selenium glycoprotein ingredient, and further research shows that the ingredient can specifically inhibit female cancer cells and has a lower normal cell inhibition activity.

The application belongs to the technical field of biotechnology, and provides a Streptococcus suis type 2 (SS2) multi-epitope inhalation subunit vaccine and application thereof.Four CTL epitopes, seven HTL epitopes and six B cell epitopes are screened from the conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, and the four CTL epitopes, the seven HTL epitopes and the six B cell epitopes are fused by AAY / GPGPG / EAAAK linkers and introduced into L7 / L12 ribosomal protein as an adjuvant to construct an inhalation subunit vaccine 1022-SpaA V3.The vaccine is intranasally primed and boosted at 60 μg, can improve respiratory mucosa sIgA and serum IgG levels, activate related immune cells, and form a mucosal and systemic double immune mechanism.The survival rate of mice after SS2 multi-strain challenge is up to 100%, and the bacterial load can be reduced.The vaccine is safe and non-toxic, inhalation can save cost, and is suitable for industrial scale production.

The application provides a preparation method of 30S ribosomal protein S1 and use of the 30S ribosomal protein S1 as an antibacterial synergist, and belongs to the technical field of biological medicines. The 30S ribosomal protein S1 in the application is a bioactive protein produced by Acinetobacter bacteria, and has the effect of enhancing the antibacterial capacity of antibiotics. In the process of being combined with streptomycin sulfate, the 30S ribosomal protein S1 greatly enhances the inhibiting capacity of streptomycin sulfate on avian pathogenic E.coli without showing the effect of inhibiting bacteria itself, which lays a foundation for future practical application, and also plays a reference role for the development of new antibacterial synergists.

The application belongs to the technical field of genetic engineering, and particularly relates to a ribosomal protein N' mutant and application thereof. The ribosomal protein N' mutant is subjected to Y190D mutation. When the ribosomal protein N' expressed by a production strain is subjected to Y190D mutation, the production of LNT II is increased by 28.6%, the production of LNnT is increased by 50%, the production of LNT is increased by 92.3%, the production of 3'-SL is increased by 13.8%, and the production of 6'-SL is increased by 20%. It can be seen that after the 190th amino acid of PriA is changed from tyrosine to aspartic acid, the production capacity is improved. When the ribosomal protein N' mutant is applied to an Escherichia coli for producing human milk oligosaccharides, the production of human milk oligosaccharides is significantly improved.

In the present invention, when there is a peak of m / z 6766 + / -permissible error of ribosomal protein L30 derived from Mycobacterium abscessus subsp. Boleti as a result of mass spectrometry of a bacterium to be detected of Mycobacterium abscessus, it is determined that the bacterium to be detected is subsp. Boleti (steps 6, 7), and if there is a peak of m / z 6766 + / -permissible error of ribosomal protein L30 derived from Mycobacterium abscessus (steps 6, 7), it is determined that the bacterium to be detected is subsp. Boleti (steps 6, 7). The method comprises the following steps: determining that a bacterium to be detected is subspecies massiliensis if a peak of m / z 8767 + / -allowable error of ribosomal protein L29 derived from the subspecies massiliensis of Mycobacterium abscessus exists (steps 8 and 9), and determining that the bacterium to be detected is subspecies abscessus of Mycobacterium abscessus if both are not present (step 10). As a result, the subspecies of Mycobacterium abscessus (Mycobacterium abscessus) can be accurately, simply and conveniently identified.